Back to the main directory
Press Release
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) by GlobeNewsWire
- M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation by GlobeNewsWire
- Osisko Metals Acquires Additional Claims Near Gaspé Copper by GlobeNewsWire
- Mise à disposition du document d’enregistrement universel Elior Group 2023/2024 by BusinessWire
- Globalink Investment Inc. Announces Charter and Trust Agreement Amendments by GlobeNewsWire
- Tandy Leather Factory Announces Agreement to Sell Headquarters Facilities by GlobeNewsWire
- Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND by GlobeNewsWire
- Tribunal Brasileño Confirma la Obligación de Tenaris de Pagar una Indemnización en relación con su Adquisición de 2012 de una Participación en Usiminas; la Decisión está sujeta a Nuevas Apelaciones by GlobeNewsWire
- Voxtur Announces Amendments to Financial Statements and MD&A for Q3 Ended September 30, 2024 by GlobeNewsWire
- Sprott Physical Gold Trust Updates Its “At-the-Market” Equity Program by GlobeNewsWire
- Sprott Physical Platinum and Palladium Trust Updates Its “At-the-Market” Equity Program by GlobeNewsWire
- Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million by BusinessWire
- Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC by GlobeNewsWire
- Turkiye Garanti Bankasi A.S.: Announcement regarding our Bank’s Corporate Governance Compliance Rating by EQS Group AG
- Communiqué de presse : ASH : le rilzabrutinib a apporté un bénéfice significatif aux patients atteints de TPI dans le cadre de la première étude de phase III positive consacrée à un inhibiteur de la BTK by GlobeNewsWire
- Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting by GlobeNewsWire
- Galapagos kondigt bemoedigende nieuwe resultaten aan van de lopende fase 1/2-studie van de CD19 CAR T-celtherapie GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom by GlobeNewsWire
- Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions by GlobeNewsWire
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) by GlobeNewsWire
- Halfords Group PLC: Total Voting Rights by EQS Group AG
- Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients by GlobeNewsWire
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader by GlobeNewsWire
- Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m by GlobeNewsWire
- Lead Real Estate Co., Ltd. Opening New Apartment Hotel, ENT TERRACE GINZA PREMIUM, in Tokyo by GlobeNewsWire